ENANTA PHARMACEUTICALS INC
ENANTA PHARMACEUTICALS INC (ENTA): 575 pipeline candidates · 44 upcoming catalysts · ~68 mo cash runway · 318 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
67.8 months
D/E 1.70 · 0% dilution
Lead: Phase 3
575 candidates
44 upcoming, next in ~13d
N/A
A transparent, data-derived signal for ENANTA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$385.4M
Cash
$34.9M
Quarterly Burn
$7.2M
Runway
67.8 mo
Revenue
$17.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (575 candidates)
| Drug | Phase |
|---|---|
| ([18F]-6F-DA) | Phase 1 |
| ([18F]-DOPA) | Phase 1 |
| [18F]FAPI-74 PET/CT | Phase 3 |
| [F-18]-FAPI-74 | Phase 2 |
| 18F-FAPI-74 | Phase 3 |
| 18F-FDG | Phase 2 |
| 24-IU oxytocin | Phase 2 |
| 48-IU oxytocin | Phase 2 |
| 5 Azacytidine | Phase 1 |
| 5% Dextrose | Phase 4 |
Showing 10 of 575 candidates. Sign up for full pipeline.
Upcoming Catalysts (44)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
130
Total value held
$343.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 7,568,110 | $95.4M |
| blackrock, inc. | 3,103,768 | $39.2M |
| farallon capital management llc | 2,871,862 | $36.3M |
| vanguard capital management llc | 2,356,098 | $29.8M |
| deep track capital, lp | 1,956,867 | $24.7M |
| vanguard portfolio management llc | 948,904 | $12.0M |
| millennium management llc | 882,097 | $11.1M |
| geode capital management, llc | 725,061 | $9.2M |
| renaissance technologies llc | 665,258 | $8.4M |
| state street corp | 562,106 | $7.1M |
Showing top 10 of 130 institutional holders of ENANTA PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ENANTA PHARMACEUTICALS INC's pipeline?
ENANTA PHARMACEUTICALS INC (ENTA) has 575 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ENANTA PHARMACEUTICALS INC's lead drug candidate?
ENANTA PHARMACEUTICALS INC's most advanced tracked candidate is ([18F]-6F-DA) (Phase 1) for Pheochromocytoma.
What is ENANTA PHARMACEUTICALS INC's next catalyst?
ENANTA PHARMACEUTICALS INC's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Z" — expected July 1, 2026.
What is ENANTA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ENANTA PHARMACEUTICALS INC has approximately 67.8 months of cash runway.
What is ENANTA PHARMACEUTICALS INC's market capitalization?
ENANTA PHARMACEUTICALS INC's market capitalization is approximately $385.4M.
Get the full picture on ENANTA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.